Review
Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies
Affiliations
- PMID: 14763130
Item in Clipboard
Review
Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies
Curr Opin Investig Drugs.
2003 Dec.
Abstract
Decitabine (DAC) is a small molecule nucleotide analog that is incorporated into DNA and traps human DNA methyltransferases. Although initially developed as a cytotoxic agent, low-dose DAC is enjoying a revival as a specific inhibitor of hypermethylation in cancer. DAC has activity in several hematological diseases, especially myelodysplastic syndrome, chronic myelogenous leukemia and acute myeloid leukemia. Clinical and preclinical advances are presented in this review.
Similar articles
-
Decitabine. MGI Pharma Inc/SuperGen Inc.IDrugs. 2004 Dec;7(12):1113-32. IDrugs. 2004. PMID: 15599805 Review.
-
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.Epigenomics. 2010 Feb;2(1):71-86. doi: 10.2217/epi.09.44. Epigenomics. 2010. PMID: 22122748 Review.
-
Decitabine has promising clinical activity in chronic myeloid leukemia.Expert Rev Anticancer Ther. 2002 Dec;2(6):620-1. Expert Rev Anticancer Ther. 2002. PMID: 12503205 No abstract available.
-
Decitabine and its role in the treatment of hematopoietic malignancies.Leuk Lymphoma. 2007 Aug;48(8):1472-81. doi: 10.1080/10428190701471981. Leuk Lymphoma. 2007. PMID: 17701577 Review.
-
Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.Curr Pharm Des. 2012;18(22):3190-7. doi: 10.2174/1381612811209023190. Curr Pharm Des. 2012. PMID: 22571698 Review.
Cited by
-
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2. Mol Cancer. 2015. PMID: 26654227 Free PMC article. Review.
-
Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Oncol Lett. 2015 Aug;10(2):761-767. doi: 10.3892/ol.2015.3253. Epub 2015 May 22. Oncol Lett. 2015. PMID: 26622566 Free PMC article.
-
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):205-10. doi: 10.3816/CLML.2010.n.032. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20511166 Free PMC article.
-
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.J Cell Mol Med. 2009 Sep;13(9B):3668-79. doi: 10.1111/j.1582-4934.2009.00661.x. J Cell Mol Med. 2009. PMID: 20196786 Free PMC article.
-
Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.DNA Repair (Amst). 2009 Dec 3;8(12):1411-23. doi: 10.1016/j.dnarep.2009.09.011. Epub 2009 Oct 15. DNA Repair (Amst). 2009. PMID: 19836314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources